China: Food, Drugs, Healthcare, Life Sciences

China is becoming an increasing focus for transactions in the pharmaceuticals sector with its growing investment into research and development, government support and a steady...

On August 9, 2024, the State Administration for Market Regulation (SAMR) released the Anti-Monopoly Guidelines for the Pharmaceutical Sector (Draft for Public Comment) (hereinafter referred to as the Pharmaceutical Anti-Monopoly Guidelines or the Guidelines) to solicit opinions from the public.

2024年8月9日，市场监管总局发布了《关于药品领域的反垄断指南（征求意见稿）》（以下简称《药品反垄断指南》或《指南》），向社会公开征૓

China is becoming an increasing focus for transactions in the pharmaceuticals sector with its growing investment into research and development, government support and a steady...

为进一步完善全链条支持创新药发展举措，推动创新药高质量发展，更好满足人民群众多元化就医用药需求，国家医保局、国家卫生健康委联

In the first half of 2025, China's healthcare and life sciences regulatory framework underwent a wave of important reforms. These developments reflect the country's continued efforts toward global alignment...

China is becoming an increasing focus for transactions in the pharmaceuticals sector with its growing investment into research and development, government support and a steady...

为进一步完善全链条支持创新药发展举措，推动创新药高质量发展，更好满足人民群众多元化就医用药需求，国家医保局、国家卫生健康委联

In the first half of 2025, China's healthcare and life sciences regulatory framework underwent a wave of important reforms. These developments reflect the country's continued efforts toward global alignment...